{'fraction_non_alphanumeric': 0.015209125475285171, 'fraction_numerical': 0.0, 'mean_word_length': 5.32, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The effect of in‐vivo dispersion and gastric emptying on glibenclamide absorption from a novel, rapidly dissolving capsule formulation

The in‐vivo dispersion and gastric emptying of a novel glibenclamide dose form have been investigated using γ‐scintigraphy and related to the absorption of glibenclamide determined by measuring glibenclamide plasma concentrations. Its absorption is determined by the rate of emptying of the dose form from the stomach with the lag time between dosing and the start of gastric emptying (and hence absorption of the dose) largely dependent on the in‐vivo disintegration time. The presence of food in the stomach has a marked effect on in‐vivo disintegration/dispersion of the dose form and hence on the lag time between dosing and the start of absorption.